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ARTICLE
Heavily and fully modiﬁed RNAs guide efﬁcient
SpyCas9-mediated genome editing
Aamir Mir 1, Julia F. Alterman1, Matthew R. Hassler1, Alexandre J. Debacker1, Edward Hudgens2,
Dimas Echeverria1, Michael H. Brodsky2, Anastasia Khvorova1,3, Jonathan K. Watts1,4 & Erik J. Sontheimer 1,3
RNA-based drugs depend on chemical modiﬁcations to increase potency and to decrease
immunogenicity in vivo. Chemical modiﬁcation will likely improve the guide RNAs involved in
CRISPR-Cas9-based therapeutics as well. Cas9 orthologs are RNA-guided microbial effectors
that cleave DNA. Here, we explore chemical modiﬁcations at all positions of the crRNA guide
and tracrRNA cofactor. We identify several heavily modiﬁed versions of crRNA and tracrRNA
that are more potent than their unmodiﬁed counterparts. In addition, we describe fully
chemically modiﬁed crRNAs and tracrRNAs (containing no 2′-OH groups) that are functional
in human cells. These designs will contribute to Cas9-based therapeutics since heavily
modiﬁed RNAs tend to be more stable in vivo (thus increasing potency). We anticipate that
our designs will improve the use of Cas9 via RNP and mRNA delivery for in vivo and ex vivo
purposes.
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CRISPR RNA-guided genome engineering has revolutio-nized research into human genetic disease and many otheraspects of biology. Numerous CRISPR-based in vivo or
ex vivo genome editing therapies are nearing clinical trials. At the
heart of this revolution are the microbial effector proteins found
in class II CRISPR-Cas systems1 such as Cas9 (type II) and
Cas12a/Cpf1 (type V)2–4.
The most widely used genome editing tool is the type II-A Cas9
from Streptococcus pyogenes strain SF370 (SpyCas9)2. Cas9 forms
a ribonucleoprotein (RNP) complex with a CRISPR RNA
(crRNA) and a trans-activating crRNA (tracrRNA) for efﬁcient
DNA cleavage both in bacteria and eukaryotes (Fig. 1a). The
crRNA contains a guide sequence that directs the Cas9 RNP to a
speciﬁc locus via base pairing with the target DNA to form an R-
loop. This process requires the prior recognition of a protospacer
adjacent motif (PAM), which for SpyCas9 is NGG. R-loop for-
mation activates the His–Asn–His (HNH) and RuvC-like endo-
nuclease domains that cleave the target strand and the non-target
strand of the DNA, respectively, resulting in a double-strand
break (DSB).
For mammalian applications, Cas9 and its guide RNAs can be
expressed from DNA (e.g., a viral vector), RNA (e.g., Cas9 mRNA
plus guide RNAs in a lipid nanoparticle), or introduced as an
RNP. Viral delivery of Cas9 results in efﬁcient editing, but can be
problematic because long-term expression of Cas9 and its guides
can result in off-target editing, and viral vectors can elicit strong
host immune responses5. RNA and RNP delivery platforms of
Cas9 are suitable alternatives to viral vectors for many applica-
tions and have recently been shown to be effective genome editing
tools in vivo6,7. RNP delivery of Cas9 also bypasses the require-
ment for Cas9 expression, leading to faster editing. Furthermore,
Cas9 delivered as mRNA or RNP exists only transiently in cells
and therefore exhibits reduced off-target editing. For instance,
Cas9 RNPs were successfully used to correct hypertrophic car-
diomyopathy (HCM) in human embryos without measurable off-
target effects8.
The versatility of Cas9 for genome editing derives from its
RNA-guided nature. The crRNA of SpyCas9 used in this study
consists of a 20-nt guide region followed by a 16-nt repeat region
(Fig. 1a). The tracrRNA consists of an anti-repeat region that
pairs with the crRNA, and also includes three stem-loops. All of
these secondary structure elements are required for efﬁcient
editing in mammalian systems9. However, unmodiﬁed RNAs are
subject to rapid degradation in circulation and within cells10,11.
Therefore, it is highly desirable to chemically protect RNAs for
efﬁcient genomic editing in hard-to-transfect cells and in vivo.
Thus, it has been previously reported that chemical modiﬁcations
in the crRNA and tracrRNA enhance stability and editing efﬁ-
ciency in vivo and ex vivo6,7,11–13. Chemical modiﬁcations
including 2′-O-methyl (2′-OMe), phosphorothioate (PS), 2′-O-
methyl thioPACE (MSP), 2′-O-methyl-PACE (MP), 2′-ﬂuoro
RNA (2′-F-RNA), and constrained ethyl (S-cEt) have previously
been employed to synthesize crRNA and tracrRNA6,11,12. The
modiﬁed RNAs not only improved Cas9 efﬁcacy, but in some
instances also improved speciﬁcity11,14. The effect of an indivi-
dual modiﬁcation varies based on the position and combination
of chemical modiﬁcations used as well as the inter- and intra-
molecular interactions with other modiﬁed nucleotides. For
instance, S-cEt was primarily used to improve oligonucleotide
intramolecular folding. Modiﬁcations were either based on the
crystal structures of Cas9 or limited to the ends of RNAs, and the
guides were not modiﬁed extensively. Nonetheless, heavily or
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Fig. 1 Initial screening of chemical modiﬁcations in the crRNA. a Schematic of Cas9 RNP paired with target DNA. The secondary structure elements of
crRNA and tracrRNA are labeled. RNA is shown in orange, whereas DNA is in gray. The PAM sequence is highlighted red and cleavage sites are marked
with arrows. b Chemical modiﬁcations used in this study. c Bar graph showing mCherry-positive cells after electroporation of HEK293T-TLR cells with
RNPs that included the indicated crRNAs and an unmodiﬁed tracrRNA. Error bars represent standard deviation (SD) resulting from at least three biological
replicates
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fully modiﬁed RNAs may have advantages in vivo10. Modiﬁed
siRNAs and ASOs substantially improve stability and potency,
and can also reduce off-target effects (though reductions in off-
target effects resulting from chemical modiﬁcations can be con-
text-dependent)15. Furthermore, extensively modiﬁed RNAs can
prevent innate immune responses16. For these and other reasons,
the abilities of siRNA and ASO drugs to succeed in clinical trials
have hinged on their complete chemical modiﬁcation and
metabolic stabilization, which greatly enhances in vivo efﬁcacy
even in cases where in vitro and cell-based activities are
decreased10. We reasoned that full chemical modiﬁcation of the
crRNA and tracrRNA would likewise enable in vivo therapeutic
applications, and set out to identify modiﬁcation patterns that are
compatible with SpyCas9 genome editing function in human
cells. We used structure-guided and systematic approaches to
introduce 2′-OMe-RNA, 2′-F-RNA, and PS modiﬁcations
(Fig. 1b) throughout guide RNAs. Our strategy yielded active
RNP complexes with both extensively and fully modiﬁed versions
of crRNAs and tracrRNAs.
Results
Structure-based design of crRNA and tracrRNA modiﬁcations.
Crystal structures of SpyCas9 have been solved as the RNP alone
or bound to one or both strands of target DNA17–20. These
structures provide detailed information regarding the interactions
between the Cas9 protein and crRNA:tracrRNA complex. We
used these structures to identify sites where Cas9 protein makes
no contacts with the crRNA or tracrRNA. Thus, in our initial
screen, 2′-OMe modiﬁcations were introduced at guide positions
7–10 and 20 (C2, Fig. 1c). Similarly, positions 21 and 27–36 in the
crRNA repeat region were also modiﬁed using 2′-OMe. To
improve nuclease stability, PS modiﬁcations were also introduced
at the 5′ end of the crRNA, yielding the C3 design (Fig. 1c and
Table 1). In parallel, we tested a crRNA that was more aggres-
sively modiﬁed to leave only nine nucleotides (nt) unprotected
(C1). Similarly, 2′-OMe modiﬁcations were also introduced into
the tracrRNA at all positions where no protein contact with the
RNA is observed. This gave rise to T1 that is 50% chemically
modiﬁed (Fig. 2 and Table 2).
The crRNAs and tracrRNAs were tested in a HEK293T cell line
stably expressing the trafﬁc light reporter (TLR) system, which
includes a GFP (containing an insertion), followed by an out-of-
frame mCherry21. Upon DSB induction, a subset of non-
homologous end-joining (NHEJ) repair events generate indels that
place mCherry in frame, leading to red ﬂuorescence. The
HEK293T-TLR cells were electroporated (Neon transfection
system) with an in vitro-reconstituted RNP complex of recombi-
nant 3xNLS-SpyCas9, crRNA, and tracrRNA. The electroporated
cells were analyzed by ﬂow cytometry (Supplementary Fig. 1) for
mCherry-positive cells. As shown in Fig. 1c, modiﬁed crRNAs C2
and C3 retain complete activity relative to the unmodiﬁed crRNA
C0, suggesting that the modiﬁcations introduced in crRNAs C2
and C3 are well tolerated by Cas9. Lipid-based delivery of the Cas9
RNP complex showed that C3 is slightly more efﬁcacious than C0
and C2 (Supplementary Fig. 2), which is not surprising given the
importance of end modiﬁcations for Cas9-based genome editing
seen previously in other cell types11. Since the overall editing
efﬁciency with lipid-based delivery was signiﬁcantly lower
compared to electroporation, we focused on the latter as our
preferred mode of Cas9 RNP delivery. Similar to C2 and C3, the
modiﬁed tracrRNA design T1 did not hinder Cas9 activity. On the
other hand, the extra modiﬁcations introduced in C1
almost completely abolished Cas9 activity in cells. We
reasoned that the 2′-OMe modiﬁcations (especially at positions
16–18 in the crRNA) are most likely to compromise Cas9 RNP
activity since nts at position 16 and 18 were shown to make
base-speciﬁc contacts with Arg447 and Arg7117. The 2′-OH of G16
in the TLR crRNA is also predicted to make a hydrogen bond with
Arg447. We chose C3 and T1 as a basis for further optimization.
Table 1 Chemically modiﬁed crRNAs used in this study
Guide Repeat
C1 GGUGAGCUCUuauuuGCGuA GuuuUAGAGCUAUGCU
C2 ggugagCUCUuauuugcguA GuuuuaGAGCUAUGCU
C3 ggugagCUCUuauuugcguA GuuuuaGAGCUAUGCU
C4 GGUGAGCUCUuauuugcguA GuuuuaGAGCUAUGCU
C5 ggugagCUCUuauuugCGuA GuuuuaGAGCUAUGCU
C6 ggugagCUCUuauuugcguA GuuuUAGAGCUAUGCU
C7 GGUGAGCUCUuauuugCGuA GuuuuaGAGCUAUGCU
C8 GGUGAGCUCUuauuugcguA GuuuUAGAGCUAUGCU
C9 GGUGAGCUCUuauuugCGuA GuuuUAGAGCUAUGCU
C10 GGUGAGCUCUUAUUugCGuA GuuuUAGAGCUAUGCU
C11 GGUGAGCUCUUAUUugcguA GuuuUAGAGCUAUGCU
C17 GGUGAGCUCUUAUUugCGuA GuuuUaGAGCUAUGCU
C18 GGUGAGCUCUUAUUugCGuA GuuuuAGAGCUAUGCU
C19 GGUGAGCUCUUAUUugCGuA GuuuuaGAGCUAUGCU
C20 GGUGAGCUCUUAUUugCGuA GuuuUAGAGCUAUGCU
C21 GGUGAGCUCUUAUUUGCGUA GUUUUAGAGCUAUGCU
C22 GGUGAGCUCUUAUUugCGuA GUuUUAGAGCUAUGCU
Lowercase: 2′-OH; uppercase and bold: 2′-OMe; uppercase and italicized: 2′-F; underlined: 3′ PS
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Fig. 2 Second round of chemical optimization of CRISPR RNAs. The
optimized crRNA designs are shown in a, whereas chemical designs of
tracrRNA are shown in b. Each crRNA was tested with the unmodiﬁed
tracrRNA T0, whereas each tracrRNA was tested with the unmodiﬁed
crRNA C0. The bar graphs show the percent of cells expressing mCherry,
±SD. Each RNA was tested in triplicate
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Empirical reﬁnement of crRNA and tracrRNA modiﬁcations.
In the second round of crRNA modiﬁcation, we introduced
additional 2′-OMe modiﬁcations into the ﬁrst 6 nt of C3 to yield
C4 (Fig. 2). In another design, 2′-OMe modiﬁcations were
incorporated at positions 17 and 18 (C5). G16 was left unmo-
diﬁed because it makes base- and backbone-speciﬁc contacts with
Cas9 and likely contributed to the low efﬁcacy of C1. Recently,
others have also observed similar constraints at position 166. In
C6, the importance of 2′-OH groups at positions 25 and 26 was
tested. The 2′-OH of these nts contacts the protein in the crystal
structure; however, they do not pair with the target DNA, and 2′-
OMe substitution at these positions may therefore be more tol-
erable. C7 and C8 were identical to C5 and C6, respectively,
except that they also contained 2′-OMe modiﬁcations in the ﬁrst
six positions. All of these crRNAs (C4–C8) were designed to
identify modiﬁcations responsible for the lower activity of C1
relative to C3.
As shown in Fig. 2 and Supplementary Fig. 3, C4–C7 retain
almost the same efﬁcacy as C0, but C8 activity was strongly
reduced. These results indicated that nts at positions 1–6 and
17–18 tolerate 2′-OH substitutions. 2′-OMe modiﬁcations at
positions 25 and 26 were tolerated in C6 but not in C8. In
addition, we synthesized a version of C8 that contained PS
linkages at several unprotected positions including 15–16, 19, and
21–23 (C9). This design also exhibited reduced editing efﬁciency
by Cas9. When tested for DNA cleavage activity in vitro, C8 and
C9 were fully active even at low RNP concentrations (Supple-
mentary Fig. 4). These results suggest the existence of structural
perturbations in C8 and C9 that are particularly acute under
intracellular conditions.
We also incorporated 2′-F-RNAs in this round of optimization
since they can increase thermal and nuclease stability of RNA:
RNA or RNA:DNA duplexes, and they also interfere minimally
with C3′-endo sugar puckering22,23. 2′-F may be better tolerated
than 2′-OMe at positions where the 2′-OH is important for RNA:
DNA duplex stability. For these reasons, we synthesized two
crRNAs based on C9 but with 2′-F modiﬁcations at positions
11–14 and/or 17–18 (C10–C11). These modiﬁcations rescued
some of C9′s diminished activity. In fact, C10 (which contained
2′-F substitutions at positions 11–14 and 17–18) performed better
than C11, in which positions 17–18 were unmodiﬁed. Our results
suggest that 2′-F substitutions can compensate for lost efﬁcacy
resulting from high 2′-OMe content. However, this may be
speciﬁc to the modiﬁcation pattern used in our crRNA design,
and the underlying reasons for this compensation remain unclear.
It is especially noteworthy that C10 retains the same activity as
the unmodiﬁed C0 but contains at least one backbone
modiﬁcation at every single phosphodiester linkage. This
represents a signiﬁcant breakthrough for Cas9-based therapeutics
because C10 has great potential to provide increased stability, and
therefore more efﬁcient editing, in vivo.
We also carried out a second round of tracrRNA optimization.
T1 was further modiﬁed by introducing 2′-OMe substitutions at
most positions where the 2′-OH groups do not make crystal
contacts with the protein. In addition, some nts that interact with
Cas9 were also modiﬁed, given that the crRNA tolerated
substitutions at many such positions. This approach produced
tracrRNAs T2–T5, which contain modiﬁcations in at least 55 out
of 67 nts. A15 is the only position that differs between T2 and T4,
whereas T3 contains additional stabilizing PS linkages at
unprotected positions relative to T2. These tracrRNAs were
tested in HEK293T-TLR cells, and the majority of 2′-OMe
chemical modiﬁcations were tolerated by the tracrRNA except at
position A15 (Fig. 2). In the crystal structure, the 2′-OH of A15
interacts with Ser104. The best-performing tracrRNA from this
round was T2, which contains 12 unmodiﬁed positions.
Furthermore, the inclusion of PS linkages at these 12 positions
reduced but did not abolish activity. This design (T3) contains at
least one chemical modiﬁcation at every position (either a PS or
ribose modiﬁcation). This also represents an important advance
for therapeutic applications of Cas9. It was again interesting to
note that while T2 was fully active in cells, it showed lower
potency when tested for DNA cleavage in vitro using low
concentrations of Cas9 (Supplementary Fig. 4). This discrepancy
suggests that net activity in cells and in vitro can be limited by
distinct factors or conditions.
The mCherry signal only results from indels producing a+ 1
frameshift, and therefore underestimates true editing efﬁciencies.
To ensure that crRNA:tracrRNA combinations do not yield false
negatives by favoring TLR indels that are out of the mCherry
reading frame, we also carried out tracking of indels by
decomposition (TIDE) analysis to analyze overall editing
efﬁciencies (Supplementary Figure 3). As shown in Supplemen-
tary Fig. 3, editing efﬁciencies measured using TIDE correlate well
with the mCherry signal.
Terminal conjugates are compatible with modiﬁed guides. We
also explored whether addition of terminal modiﬁcations such as
ﬂuorophores, N-acetylgalactosamine (GalNAc), or cholesterol-
triethylene glycol (TEGChol) are tolerated by the crRNA and the
tracrRNA. Such modiﬁcations can be useful for microscopy, and
for monitoring cellular or tissue-speciﬁc RNA uptake. We
introduced 5′-Cy3 modiﬁcations on crRNAs C10 and C11 to
yield C12 and C13, respectively (Supplementary Table 1). We
also covalently attached TegChol or GalNAc to the 3′ end of C12
or C13 to obtain C14 and C15, respectively. Most crRNA mod-
iﬁcations were tolerated on both ends, though some loss of
function was observed with C13, C14, and C16 in cells and
in vitro (Supplementary Figs. 3 and 4). In contrast, C15 was
essentially inactive. T5 containing a 3′-TegChol was also non-
functional, not surprisingly given the 2′-OMe substitution at A15.
Table 2 Chemically modiﬁed tracrRNAs used in this study
Anti-repeat Stem-loop 1 Linker Stem-loop 2 Stem-loop 3
T1 AGCAUAGcaaguuAaaau aagGcuAgucC guuauca ACUUGAAAAAGUg gcaCCGagucgGUGCUUU
T2 AGCAUAGCAAGuuAaAAu AAGGcuAgucC guuAUCA ACUUGAAAAAGUG GCACCGAGUCGGUGCUUU
T3 AGCAUAGCAAGuuAaAAu AAGGcuAgucC guuAUCA ACUUGAAAAAGUG GCACCGAGUCGGUGCUUU
T4 AGCAUAGCAAGuuAAAAu AAGGcuAgucC guuAUCA ACUUGAAAAAGUG GCACCGAGUCGGUGCUUU
T6 AGCAUAGCAAGuuAaAAU AAGGCUAgUCC guuAUCA ACUUGAAAAAGUG GCACCGAGUCGGUGCUUU
T7 AGCAUAGCAAGuUAaAAU AAGGCUAGUCC guuAUCA ACUUGAAAAAGUG GCACCGAGUCGGUGCUUU
T8 AGCAUAGCAAGUUAAAAU AAGGCUAGUCC GUUAUCA ACUUGAAAAAGUG GCACCGAGUCGGUGCUUU
Lowercase: 2′-OH; uppercase and bold: 2′-OMe; uppercase and italicized: 2′-F; underlined: 3′ PS
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Complete chemical modiﬁcation of dual guides. We built upon
the best-performing individual chemical conﬁgurations (C10 and
T2) to attempt to deﬁne combined crRNA:tracrRNA modiﬁcation
patterns that are compatible with SpyCas9 RNP function. Because
crRNA 2′-F substitutions were largely tolerated (Fig. 2), and in
some cases even compensated for the loss of efﬁcacy caused by 2′-
OMe substitutions, we added several 2′-F modiﬁcations to C10
and T2. In addition, because we had observed that simultaneous
2′-OMe modiﬁcation at positions 25 and 26 negatively affected
efﬁcacy in some cases (e.g., C8), we tested these two positions for
their sensitivities to 2′-F or individual 2′-OMe substitutions. We
also incorporated additional 2′-F modiﬁcations in the tracrRNAs.
In positions where the nucleobases interact with Cas9, we took
two approaches to modiﬁcation. While we suspected that protein-
interacting sites would be less tolerant of modiﬁcation, it was
difﬁcult to predict whether steric constraints or charge interac-
tions were more important. To address this issue, we synthesized
three different tracrRNAs: one where all protein-interacting sites
were left as 2′-OH (T6), another where all were converted to 2′-F
(T8), and another where only the nucleobases that interact with
nonpolar amino acids were converted to 2′-F (T7). Using this
systematic approach, crRNAs C17–C22 and tracrRNAs T6–T8
were synthesized and tested (Fig. 3a).
When C17–C22 were used with either T2 or the T0 control (20
pmol RNP), all showed comparable efﬁcacy as the C0 and C10
crRNAs (Fig. 3b). This includes the fully modiﬁed C21 that is
either 2′-F- or 2′-OMe-substituted at every position. To our
knowledge, completely modiﬁed and fully functional crRNA has
not been reported previously. C21 loses some efﬁcacy when
combined with T6–T8 and is also less potent than C0 when lower
(3 pmole) doses of RNP are delivered (Supplementary Fig. 5).
These losses may be due to compromised base pairing between
the heavily modiﬁed repeat:anti-repeat duplexes. Across all
tracrRNAs tested, C20 exhibits the highest editing efﬁciency. In
addition, at 3 pmol RNP, C20 is more potent than unmodiﬁed
C0, suggesting enhanced stability in cells (Supplementary Fig. 5).
Although C20 includes six ribose sugars, each is adjacent to a PS
modiﬁcation, leaving no unmodiﬁed linkages in the crRNA.
Among T6–T8, the best-performing tracrRNA was T6,
especially with modiﬁed crRNAs including C20. The fully
modiﬁed tracrRNA (T8) compromised the potency of all crRNAs
tested but retains some function (~5% editing with 20 pmol RNP)
with C19 and C20 (Fig. 3b). To test whether T8 activity improves
at higher doses, we electroporated cells with 100 pmol Cas9 RNP.
We found that by using a higher amount of Cas9 RNP, the
editing efﬁciency of T8 in combination with C0 or C20 is rescued
to the same level as observed using 20 pmol of Cas9 RNP with
C0:T0 (Fig. 3). Furthermore, at higher doses, the efﬁcacy of C20:
T8 is almost as high as that of C20:T0. Lastly, the editing
efﬁciency of the fully modiﬁed pair (C21:T8) is within ~twofold
of the unmodiﬁed (C0:T0) crRNA:tracrRNA pair. To our
knowledge, efﬁcient editing with a fully modiﬁed crRNA:
tracrRNA combination has not been demonstrated previously.
While the editing efﬁciency is not as high as that of the
unmodiﬁed RNAs in cells, the increased serum stability afforded
by the fully chemically optimized C21:T8 combination (Supple-
mentary Fig. 6) would likely provide signiﬁcant beneﬁts in vivo,
as observed for fully modiﬁed siRNAs and ASOs.
Modiﬁed guides support genome editing at endogenous loci.
To verify that our crRNA designs are compatible with different
guide sequences, including those targeting endogenous human
genes, we tested the C10, C20, and C21 designs targeting the
huntingtin (HTT), human hemoglobin β (HBB), and vascular
endothelial growth factor A (VEGFA) genes14,24. VEGFA and
HBB target sites were chosen for their therapeutic potential as
well as the fact that they have been previously validated for
genome editing. The HTT site, on the other hand, is a potential
polymorphic target for Huntington’s disease treatment. As shown
in Fig. 4a, b, HTT-C10 and HTT-C20 performed as well as the
minimally modiﬁed HTT-C0 when paired with T2 and T0. T6
and T7 are more efﬁcacious with the modiﬁed C10 compared to
minimally modiﬁed C0. The fully modiﬁed HTT-C21 performed
as well as the HTT-C0 when tested with T2. However, similar to
the TLR target site, some loss of potency is observed with the fully
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Fig. 3 Cas9 tolerates heavily and fully modiﬁed crRNA:tracrRNA. a, b Each crRNA was tested with tracrRNAs T0, T2, and T6–T8 using 20 pmol of Cas9
RNP. c HEK293T-TLR cells were also electroporated with 100 pmol of the indicated RNPs to test whether heavily modiﬁed RNAs regain functionality at
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modiﬁed T8. However, T8 did support editing with efﬁciencies
comparable to T0 when paired with C20. Similar results were
obtained at the HBB and VEGFA target sites (Fig. 4c, d): our
potent RNA designs (C20:T2) performed as well as the minimally
modiﬁed designs, and the fully modiﬁed dual guides exhibited
some loss in potency. Furthermore, electroporations performed
using 3 pmol of RNP suggested that C10 and C20 may be more
efﬁcacious (but never less efﬁcacious) than the unmodiﬁed
crRNA, similar to what was observed in Supplementary Fig. 4, but
this effect seemed to vary between target sites (Supplementary
Fig. 7). C20 also showed higher potency compared to C0 when
tested in human embryonic stem cells (hESC) (Fig. 4e). In hESC
the highest potency was achieved using the heavily modiﬁed
combination C20:T2. Furthermore, the fully modiﬁed crRNA C21
was just as efﬁcacious as the minimally modiﬁed C0. We also
examined editing in HEK293T cells at the top off-target site for
both HBB and VEGFA, as validated previously14,24. The modiﬁed
crRNAs do not signiﬁcantly affect off-target editing, though the
fully modiﬁed C21:T8 may provide slight speciﬁcity improve-
ments compared to the less heavily modiﬁed designs (Supple-
mentary Fig. 8). Collectively, these results demonstrate that our
modiﬁed crRNA designs can be applied to endogenous target sites.
It has previously been shown that crRNA and tracrRNA can be
fused with a GAAA tetraloop or other linkers to yield a single-
guide RNA (sgRNA) with enhanced efﬁcacy. Given the possibility
that repeat:anti-repeat interactions could affect efﬁcacy, we
explored the pairing between the repeat and anti-repeat of
crRNA and tracrRNA. We designed and synthesized GC-rich
crRNAs (hiGC C1–C4) and tracrRNAs (hiGC T1–T4) to
improve pairing between crRNA and tracrRNA (Supplementary
Table 1). All of the modiﬁed RNAs outperformed in vitro
transcribed sgRNA as well as synthetic, unmodiﬁed dual RNAs
(Supplementary Fig. 9). Furthermore, at lower concentrations,
hiGC C1 exhibited increased potency relative to non-optimized
versions of unmodiﬁed or modiﬁed RNAs (Supplementary Fig. 9).
However, this trend does not hold true in HTT-hiGC C1
(Supplementary Fig. 9). Therefore, these mutant sequences may
be superior to wild-type sequences in a guide sequence-speciﬁc
manner.
Modiﬁed guides support precise editing. Many genome engi-
neering applications require precise genome editing. For precise
repair, a donor DNA can be provided that acts as a template for
homology-directed repair (HDR) of a Cas9-mediated DSB. The
TLR system21 allows the use of a donor that restores the func-
tional sequence of the GFP, yielding green ﬂuorescence (NHEJ
repairs under these conditions still yield mCherry expression and
red ﬂuorescence, so both repair outcomes can be scored simul-
taneously). To ensure that our modiﬁed RNA designs are com-
patible with HDR, we tested the crRNAs C0, C10, C20, and C21
in combination with tracrRNAs T0, T2, or T8 in HEK293T-TLR
cells. In this case, we also provided an 800 bp donor template that
contains the GFP sequence (Fig. 5a). Our fully and heavily
modiﬁed crRNA designs (C10, C20, and C21), when paired with
T0 or T2, supported HDR with comparable efﬁciency as the end-
modiﬁed C0 (Fig. 5b). Although T8 supported HDR at above-
background levels (Fig. 5b and Supplementary Data 1), GFP
induction was relatively inefﬁcient. This can be attributed to
lower overall editing with 20 pmoles of Cas9 RNP (Fig. 5c), as
described above. As with NHEJ repairs, HDR activity of the fully
modiﬁed C21:T8 was recovered using high dose of Cas9 (Fig. 5d).
These experiments demonstrate that our fully and heavily mod-
iﬁed RNAs can be used for precise genome editing.
Discussion
Engineered CRISPR systems have the potential to transform the
treatment of inherited diseases via genome editing-based cures.
Nonetheless, safe, effective, and target-tissue-speciﬁc delivery of
CRISPR effector proteins and their small RNA guides represents a
major barrier to clinical application. Because of the central
importance of the small RNA guides, CRISPR’s clinical devel-
opment could beneﬁt from technologies developed for earlier
generations of nucleic acid therapeutics such as siRNAs and
antisense oligonucleotides. Two critical realizations have led to a
surge of recent successes with these therapeutic modalities: (i) the
importance of complete chemical modiﬁcation (i.e., the removal
or modiﬁcation of 100% of 2′-OH groups) to confer metabolic
stability and suppress immune system activation without
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nanoparticle formulation; and (ii) the utility of appended che-
mical conjugates to tune biodistribution properties and engage
cell-surface components that facilitate uptake10. These principles
should enable the safe, effective delivery of CRISPR guides, either
pre-loaded into their protein effectors [ribonucleoprotein (RNP)
delivery] or administered in tandem with mRNAs or viral vectors
that encode the effector protein.
Here we have used a structure-guided approach, combined
with systematic addition of modiﬁcations, to identify heavily or
fully modiﬁed crRNAs and tracrRNAs that direct SpyCas9 gen-
ome editing in human cells. Two pairs of crRNA:tracrRNA stand
out as particularly promising. First, C20:T2 is our most potent
combination, and both RNAs contain ribose substitutions at
>80% of their nts. Furthermore, C20 contains at least one che-
mical modiﬁcation (2′-OMe, 2′-F, or PS) at every single position.
The C20:T2 combination is more potent than its unmodiﬁed
crRNA:tracrRNA counterpart when tested in human cells. Sec-
ond, although the C21:T8 combination exhibits reduced potency
in human cells, its signiﬁcant functionality is still noteworthy
because it is completely devoid of ribose sugars. This will greatly
ease chemical synthesis, enhance in vivo stability, and provide a
springboard toward additional improvements (such as terminally
appended chemical functionalities) that facilitate delivery and
efﬁcacy during clinical applications of genome editing.
Methods
Synthesis of oligonucleotides. CRISPR guides were synthesized at 1 µmole scale
on an Applied Biosystems 394 DNA synthesizer. BTT (0.25 M in acetonitrile,
ChemGenes) was used as activator. 0.05 M iodine in pyridine:water (9:1) (TEDIA)
was used as oxidizer. DDTT (0.1 M, ChemGenes) was used as sulfurizing agent. A
total of 3% TCA in DCM (TEDIA) was used as deblock solution. Oligonucleotides
were grown on 1000 Å CPG functionalized with Unylinker (~42 µmol/g). RNA and
2′-OMe phosphoramidites (ChemGenes) were dissolved in acetonitrile to 0.15 M;
the coupling time was 10 min for each base. The nucleobase protecting groups were
removed with a 3:1 NH4OH:EtOH solution for 48 h at room temperature or 40%
aqueous methylamine for 15 min at 65 °C. Deprotection of the TBDMS group was
achieved with DMSO:NEt3•3HF (4:1) solution (500 µL) at 65 °C for 3 h. RNA
oligonucleotides were then recovered by precipitation in 3M NaOAc (25 µL) and
n-BuOH (1 mL), and the pellet was washed with cold 70% EtOH and resuspended
in 1 mL RNase-free water.
TracrRNA was synthesized on an Expedite ABI DNA/RNA synthesizer.
Sequences were prepared at 1 µmole scale using phosphoramidites (ChemGenes)
prepared as 0.15 M solutions in dry acetonitrile. Trityl groups were removed using
3% dichloroacetic acid (DCA) in toluene for 100 s. All other reagents are the same
as above. Deprotection and puriﬁcation of oligonucleotides were achieved by the
addition of 1 mL of 40% aq. methylamine at 60 °C for 13 min. The oligonucleotide
solutions were then frozen in liquid nitrogen and lyophilized to dryness in a
Speedvac concentrator. Deprotection of the TBDMS group was achieved with
DMSO:NEt3•3HF (4:1) solution (500 µL) at 65 °C for 3 h. The oligonucleotides
were then recovered by precipitation in 3M NaOAc (25 µL) and n-BuOH (1 mL),
and the pellet was washed with cold 70% EtOH and resuspended in 1 mL RNase-
free water. If the oligo did not contain any 2′TBDMS group, the TBDMS
deprotection was omitted.
Puriﬁcation of oligonucleotides was carried out by high performance liquid
chromatography using a 1260 inﬁnity system with an Agilent PL-SAX 1000 Å
column (150 × 7.5 mm, 8 µm). Buffer A: 30% acetonitrile in water; Buffer B: 30%
acetonitrile in 1 M NaClO4 (aq). Excess salt was removed with a Sephadex Nap-10
column.
Oligonucleotides were analyzed on an Agilent 6530 Q-TOF LC/MS system with
electrospray ionization and time-of-ﬂight ion separation in negative ionization
mode. Liquid chromatography was performed using a 2.1 × 50-mm AdvanceBio
oligonucleotide column (Agilent Technologies, Santa Clara, CA). The data were
analyzed using Agilent Mass Hunter software. Buffer A: 100 mM
hexaﬂuoroisopropanol with 9 mM triethylamine in water; Buffer B: 100 mM
hexaﬂuoroisopropanol with 9 mM trimethylamine in methanol. Purities are
provided in Supplementary Table 3.
Cell culture. A human HEK293T stable cell line expressing the trafﬁc light reporter
system was kindly provided by Wen Xue’s lab in the RNA Therapeutics Institute at
UMass Medical School. The original HEK293T cells were obtained from ATCC.
These cells were cultured in Dulbecco-modiﬁed Eagle’s minimum essential med-
ium (DMEM; Life Technologies). DMEM was also supplemented with 10% fetal
bovine serum (FBS; Sigma). HEK293T cells were obtained from ATCC and cul-
tured in the same conditions. H1 human embryonic stem cells were obtained from
WiCell and cultured using feeder-free mTeSR medium (STEMCELL). Cells were
grown in a humidiﬁed 37 °C, 5% CO2 incubator.
Expression and puriﬁcation of 3xNLS-SpyCas9. The pMCSG7 vector expressing
the Cas9 from Streptococcus pyogenes was kindly provided by Dr. Scot Wolfe’s lab.
In this construct, the Cas9 also contains three nuclear localization signals (NLSs).
Rosetta DE3 strain of Escherichia coli was transformed with the 3xNLS-SpyCas9
construct. For expression and puriﬁcation of 3xNLS-SpyCas9, a previously estab-
lished protocol was used2. The bacterial culture was grown at 37 °C until an OD600
of 0.6 was reached. Then, the bacterial culture was cooled to 18 °C, and 1 mM
isopropyl β-D-1-thiogalactopyranoside (IPTG; Sigma) was added to induce protein
expression. Cells were grown overnight for 16–20 h.
The bacterial cells were harvested and resuspended in lysis buffer [50 mM Tris-
HCl (pH 8.0), 5 mM imidazole]. 10 µg/mL of lysozyme (Sigma) was then added to
the mixture and incubated for 30 min at 4 °C. This was followed by the addition of
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1 × HALT Protease Inhibitor Cocktail (ThermoFisher). The bacterial cells were
then sonicated and centrifuged for 30 min at 18,000 × g. The supernatant was then
subjected to Nickel afﬁnity chromatography (Qiagen). The elution fractions
containing the SpyCas9 were then further puriﬁed using cation exchange
chromatography using a 5 mL HiTrap S HP column (GE). This was followed by a
ﬁnal round of puriﬁcation by size-exclusion chromatography using a Superdex-200
column (GE). The puriﬁed protein was concentrated and ﬂash frozen for
subsequent use.
Electroporations of mammalian cells. The HEK293T and hESC cells were elec-
troporated using the Neon transfection system (ThermoFisher) according to the
manufacturer’s protocol. Brieﬂy, 20–100 picomoles of 3xNLS-SpyCas9 were mixed
with 25–125 picomoles of crRNA:tracrRNA in buffer R (ThermoFisher) and
incubated at room temperature for 20–30 min. For electroporations involving HDR
experiments, 400 ng of dsDNA donor was also added to the mixture. This Cas9
complex was then mixed with ~100,000 cells, which were already resuspended in
buffer R. This mixture was electroporated with a 10 µL Neon tip and then plated in
24-well plates containing 500 µL of the appropriate media. The cells were stored in
a humidiﬁed 37 °C and 5% CO2 incubator for 2–3 days for HEK293T and a week
for hESCs.
Flow cytometry. The electroporated HEK293T cells were analyzed on MACS-
Quant® VYB from Miltenyi Biotec. For mCherry detection, the yellow laser (561
nm) was used for excitation and 615/20 nm ﬁlter used to detect emission. At least
20,000 events were recorded and the subsequent analysis was performed using
FlowJo® v10.4.1. Cells were ﬁrst sorted based on forward and side scattering (FSC-
A vs SSC-A) to eliminate debris (Supplementary Figure S1). Then, cells were gated
using FSC-A and FSC-H to select single cells. Finally, mCherry signal was used to
select for mCherry-expressing cells. The percent of cells expressing mCherry was
calculated and reported in this study as a measure of Cas9-based genome editing.
Indel analysis by TIDE. The genomic DNA from cells was harvested using DNeasy
Blood and Tissue kit (Qiagen) as recommended by the manufacturer. Approxi-
mately 50 ng of genomic DNA was used to PCR amplify a ~700 bp fragment using
primers shown in Supplementary Table 2. The PCR reactions were subsequently
puriﬁed using a QIAquick PCR Puriﬁcation kit (Qiagen). The PCR fragments were
then sequenced by Sanger sequencing and the trace ﬁles were subjected to indel
analysis using the TIDE web tool (https://tide.deskgen.com/).
In vitro DNA cleavage assays. The trafﬁc light reporter plasmid (Addgene:
31482) was linearized with restriction enzyme EcoRI (N.E.B.) for 1 h, 37 °C in NEB
buffer 3, followed by heat inactivation for 20 min at 65°C. For the Cas9 digest, 200
ng of linearized plasmid DNA was added to pre-formed RNP complexes (8 pmol or
0.8 pmol) and incubated for 1 h at 37°C in 25 µl NEB buffer 3. Cut DNA was
puriﬁed using Zymo DNA puriﬁcation columns and separated on a 1% agarose gel
run at 100 V. Relative intensities of full length and Cas9-cut DNA fragments were
determined using ImageJ software.
Serum stability assays. A 10 µM Cas9 RNP complex was ﬁrst assembled in
cleavage buffer [20 mM HEPES (pH 7.5), 250 mM KCl and 10 mM MgCl2]. Then,
2 µM Cas9 RNP was incubated with 8% FBS in a 50 µL reaction at 37 °C. Then, at
time points of 0, 1, and 20 h, 10 µL of the reaction mixture was treated with
Proteinase K and then 10 µL of quench buffer (90% formamide and 25 mM EDTA)
was added to the solution. The reaction mixture was resolved on a 10% denaturing
polyacrylamide gel containing 6M Urea. The gel was stained with SYBR safe and
visualized on Typhoon FLA imager.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the paper and supplementary information. Any other
data related to this manuscript are available from the corresponding author on
reasonable request.
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